A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea.
Abstract
Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts. Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. Multiple answers were allowed for some questions. Results: Most clinicians agreed that there is a need for standardization of TACE application through specific scoring systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm (n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered ineffective. Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment guidelines in Korea.
참고문헌 (25)
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Burrel M, "Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation(TACE)using Drug Eluting Beads. Implications for clinical practice and trial design", J Hepatol, 56, pp.1330~1335 (2012)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Kim BK, "Applicability of BCLC stage for prognostic stratification in comparison with other staging systems : single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma", Liver Int, 32, pp.1120~1127 (2012)
- Terzi E, "Response rate and clinical outcome of HCC after first and repeated cTACE performed"on demand"", J Hepatol, 57, pp.1258~1267 (2012)
- Bolondi L, "Heterogeneity of patients with intermediate(BCLC B)Hepatocellular Carcinoma : proposal for a subclassification to facilitate treatment decisions", Semin Liver Dis, 32, pp.348~359 (2012)
- Kudo M, "Transarterial chemoembolization failure", refractoriness : JSHLCSGJ criteria 2014 update, pp.87(Suppl 1), 22~31
- McGlynn KA, "Global epidemiology of hepatocellular carcinoma : an emphasis on demographic and regional variability", Clin Liver Dis, 19, pp.223~238 (2015)
- Kim HY, "Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma", J Gastroenterol Hepatol, 27, pp.1051~1056 (2012)
- Kudo M, "Report of the 19th follow-up survey of primary liver cancer in Japan", Hepatol Res, 46, pp.372~390 (2016)
- Kim DY, "Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma", Aliment Pharmacol Ther, 35, pp.1343~1350 (2012)
- Georgiades C, "Lack of response after initial chemoembolization for hepatocellular carcinoma : does it predict failure of subsequent treatment?", Radiology, 265, pp.115~123 (2012)
- Jung ES, "Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization", J Hepatol, 58, pp.1181~1187 (2013)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
- Kadalayil L, "A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer", Ann Oncol, 24, pp.2565~2570 (2013)
- Park Y, "Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score", Liver Int, 36, pp.100~107 (2016)
- Sieghart W, "The ART of decision making : retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 57, pp.2261~2273 (2013)
- Kudo M, "Assessment for retreatment(ART)score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 59, pp.2424~2425 (2014)
- Terzi E, "The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series", Dig Dis, 32, pp.711~716 (2014)
- Adhoute X, "Retreatment with TACE : the ABCR SCORE, an aid to the decisionmaking process", J Hepatol, 62, pp.855~862 (2015)
- Tseng CL, "The effectiveness of ART score in selecting patients for transarterial chemoembolization retreatment: a cohort study in Taiwan", Medicine (Baltimore), 94, pp.e1659~ (2015)
- Pipa-Muñiz M, "The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study", Gastroenterol Hepatol, 40, pp.515~524 (2017)
- Pinato DJ, "Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma : a multi-center comparative study", Oncotarget, 7, pp.44705~44718 (2016)
- Kim BK, "Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation", Eur J Cancer, 49, pp.826~834 (2013)
- Gillmore R, "EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization", J Hepatol, 55, pp.1309~1316 (2011)